🧠 Food for thought

Implications, context, and why it matters.

Earendil’s valuation leans on big pharma checks tied to specific programs

• The partnerships carry clear financial stakes for a pre-IPO price, even before any product launch.
• A Sanofi agreement for two bispecific autoimmune candidates brings $125 million upfront, with as much as $1.7 billion in total value 1.
• A separate WuXi XDC collaboration, a Hong Kong-listed biotech services company, targets antibody-drug conjugates for cancer and can reach $885 million 2.
• Large upfront payments from established drugmakers give Earendil early revenue linked to defined assets, which supports its AI platform’s credibility long before commercialization.

A Hong Kong IPO looks like a pragmatic choice amid US-China tensions

• Hong Kong offers a listing venue that can reduce political friction compared with a US exchange.
• Earendil is incorporated in Delaware, while its operational affiliate sits in Beijing and it works with Chinese partners such as WuXi XDC 3.
• That footprint can draw tougher questions in the US, especially after the BIOSECURE Act in December 2025, a US law aimed at limiting collaboration with certain Chinese biotech firms 3.
• If the Hong Kong IPO succeeds, it can finance Earendil and also serve as a template for global biotechs managing US-China business ties, while strengthening Hong Kong’s standing as a more neutral capital market.